AstraZeneca PLC (LON:AZN – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine analysts that ...

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates ...

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Berenberg Bank in a report issued on Monday, MarketBeat reports. They presently have a GBX 140 ...

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

The counterfeit versions of the cancer immunotherapy Imfinzi have been found in Armenia, Lebanon, and Türkiye.

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...

Different immunotherapies have been approved for each type of cancer. Tecentriq and Imfinzi may be used along with chemotherapy as the first treatment for advanced cancers. Tecentriq and Imfinzi can ...